Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, shares new data at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) showing how its GuardantINFORM™ real-world clinical-genomic platform can be used to gain deeper insights into patients’ treatments and associated response to support the development of more effective therapies for biomarker-defined cancers. The data presented highlight treatment resistance in estrogen receptor positive (ER-positive), HER-2 negative metastatic breast cancer patients.
“While we’ve seen improved outcomes for patients with ER-positive metastatic breast cancer, many eventually develop ESR1 resistance after undergoing endocrine therapy; and new data from patients treated with CDK4/6 inhibitors suggest that clinical outcomes are impacted by a patient’s molecular subtype,” said Helmy Eltoukhy, Guardant Health CEO. “The results presented during SABCS demonstrate the power of our GuardantINFORM platform to deliver real-world clinical-genomic insights to help guide more precise oncology treatments and accelerate drug development efforts for these difficult to treat breast cancers.”
The abstracts, now online, show how this robust platform helps characterize molecular tumor evolution and treatment resistance mechanisms throughout each patient’s treatment journey.
- Abstract PS18-15: “Real-world clinical-genomic data identifies the ESR1 clonal and subclonal circulating tumor DNA (ctDNA) landscape and provides insight into clinical outcomes” shows how the data from our Guardant360 liquid biopsy dataset demonstrate the heterogeneity of ESR1 mutations associated with endocrine therapy treatment.
- Abstract PS18-28: “Genomic heterogeneity and associated clinical outcomes of breast cancers treated with CDK4/6 inhibitors: Insights from real-world clinical genomic data” suggests new potential mechanisms of acquired resistance.
- Abstract OT-07-01: “Guardant360® related clinical outcomes in patients who share medical records-breast cancer (GRECO-B)” shows how Guardant Health takes a novel patient-centric approach to enrolling Guardant360 breast cancer patients into this siteless, prospective, observational health outcomes study to create a more comprehensive view of patients’ clinical journey.
The GuardantINFORM platform is an in silico platform that combines de-identified longitudinal clinical information and genomic data collected from our Guardant360 liquid biopsy test. With data from over 135,000 patients, this real-world clinical-genomic dataset of advanced cancer patients is one of the largest in oncology. Notable applications include targeted drug development, clinical trial optimization, and post-marketing studies.
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients. These tests fuel development of its LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential benefits and advantages of the GuardantINFORM platform, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. Such risks and uncertainties include those discussed under the caption “Risk Factors” in Guardant Health’s Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Report on Form 10-Q for the period ended March 31, 2020, and in its other reports filed with the Securities and Exchange Commission. These forward-looking statements are based on current expectations, forecasts, assumptions and information available to Guardant Health as of the date hereof, and actual outcomes and results could differ materially from these statements due to a number of factors, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release. Investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Guardant Health.
Source: Guardant Health, Inc.